XBKK
APCO
Market cap51mUSD
Nov 12, Last price
2.86THB
Name
Asian Phytoceuticals PCL
Chart & performance
P/E
30.97
P/S
8.57
EPS
0.09
Div yield, %
6.29%
Shrs. gr., 5y
—
Rev. gr., 5y
-4.17%
Revenues
200m
-5.06%
Net income
55m
+1.28%
CFO
60m
+59.51%
Dividend
Apr 28, 20260.091 THB/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Asian Phytoceuticals Public Company Limited engages in the research and development, manufacture, and distribution of healthcare and natural extracts-based beauty products in Thailand. The company offers cream and lotion products in bottles and tubes for massage to tighten the skin and reduce the desired area, and facial lotion products; and products for reverse aging, anti-aging, and longevity. It is also involved in the research on mangosteen under the project name Operation BIM. It also exports its products. The company was formerly known as Natural Cosmetics Research Co., Ltd. and changed its name to Asian Phytoceuticals Public Company Limited in July 2005. Asian Phytoceuticals Public Company Limited was founded in 1988 and is headquartered in Lamphun, Thailand.
Key people
Apinya Ulumpanon
Managing Director of Finance and Accounting · since 2011
Chanthip Thasuya
Vice President of Production
Suriphorn Triyaprichaya
Vice President of Administration Office
Sirithip Viriyachitra
Managing Director of Research and Development · since 2012
Phichet Viriyachitra
Chairman of the Management Board, Chief Executive Officer, Managing Director, Director · since 2014
Chinakarn Samalapha
Chief Operating Officer, Executive Director · since 2018
Executive Director, Director · since 2005
Warakorn Samkoset
Independent Director
Aruni Viriyachitra
Executive Director, Company Secretary, Director · since 2014
Krairit Bunyakiat
Independent Director · since 2011
Phraiphon Khumsap
Independent Director · since 2011
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||